Relation between plasma homocysteine, gene polymorphisms of homocysteine metabolism-related enzymes, and angiographically proven coronary artery disease

European Journal of Internal Medicine

Volumn 18, Issue 6, 2007, Pages 474-483

  Laraqui, Abdelilah ^a,b,c   Allami, Abdellatif ^a,d   Carrié, Alain ^c   Raisonnier, Alain ^c   Coiffard, Anne Sofie ^c   Benkouka, Fatima ^b   Bendriss, Abdenabi ^d   Benjouad, Abdelaziz ^b   Bennouar, N ^a   El Kadiri, Nizar ^a   Benomar, Anwar ^a   Fellat, Seddik ^a   Benomar, Mohamed ^e  

^a Ligue Nationale de Lutte Contre les Maladies Cardiovasculaires   (Morocco)

^b FACULTÉ DES SCIENCES   (Morocco)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d ABDELMALEK ESSAADI UNIVERSITY   (Morocco)

^e IBN SINA HOSPITAL   (Morocco)

Author keywords

Coronary artery disease; Genes; Homocysteine; Metabolism; Risk factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); HOMOCYSTEINE; METHIONINE SYNTHASE;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CARDIAC PATIENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; ENZYME METABOLISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROTEIN BLOOD LEVEL; RISK FACTOR; SMOKING; STATISTICAL SIGNIFICANCE;

EID: 34548492494     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2007.02.020     Document Type: Article

References (71)

1. Boushey C.J., Beresford S.A., Omenn G.S., and Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 274 (1995) 1049-1057
2. Christensen B., Frosst P., Lussier-Cacan S., Selhub J., Goyette P., Rosenblatt D.S., et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 17 (1997) 569-573
3. Graham I.M., Daly L.E., Refsum H.M., Robinson K., Brattström L.E., Ueland P.M., et al. Plasma homocysteine as a risk factor for vascular disease: the European Concerted Action Project. JAMA 277 (1997) 1775-1781
4. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 (1997) 230-236
5. Eikelboom J.W., Lonn E., Genest J., Hankey G., and Yusuf S. Homocysteine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 131 (1999) 363-375
6. Verhoef P., and Stampfer M. Epidemiology of vascular and thrombotic associations. In: Carmel R., and Jacobsen D. (Eds). Homocysteine in health and disease (2001), Cambridge University Press, Cambridge 357-370
7. Ford E.S., Smith S.J., Stroup D.F., Steinberg K.K., Mueller P.W., and Thacker S.B. Homocysteine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 31 (2002) 59-70
8. Robinson K. Homocysteine and coronary artery disease. In: Carmel R., and Jacobsen D. (Eds). Homocysteine in health and disease (2001), Cambridge University Press, Cambridge 371-383
9. Ueland P.M., Refsum H., Beresford S.A., and Vollset S.E. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72 (2000) 324-332
10. Tsai M.Y., Bignell M., Yang F., Welge B.G., Graham K.J., and Hanson N.Q. Polygenic influence on plasma homocysteine: association of two prevalent mutations, the 844ins68 of cystathionine β-synthase and A2756G of methionine synthase, with lowered plasma homocysteine levels. Atherosclerosis 149 (2000) 131-137
11. Dekou V., Gudnason V., Hawe E., Miller G.J., Stansbie D., and Humphries S.E. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost 85 (2001) 67-74
12. Clayton D., and McKeigue P.M. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet 358 (2001) 1356-1360
13. Kraus J.P., Oliveriusova J., Sokolova J., Kraus E., Vlcek C., de Franchis R., et al. The human cystathionine β-synthase (CβS) gene: complete sequence, alternative splicing, and polymorphisms. Genomics 52 (1998) 312-324
14. Rozen R. Polymorphisms of folate and cobalamin metabolism. In: Carmel R., and Jacobsen D. (Eds). Homocysteine in health and disease (2001), Cambridge University Press, Cambridge 259-269
15. Boers G.H., Smals A.G., Trijbels F.J., Fowler B., Bakkeren J.A., Schoonderwaldt H.C., et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 313 (1985) 709-715
16. Clarke R., Daly L., Robinson K., Naughten E., Cahalane S., Fowler B., et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 324 (1991) 1149-1155
17. Dekou V., Gudnason V., Hawe E., Miller G.J., Stansbie D., and Humphries S.E. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost 85 (2001) 67-74
18. Nordstrom M., and Kjellstrom T. Age dependency of cystathionine beta-synthase activity in human fibroblasts in homocyst(e)inemia and atherosclerotic vascular disease. Atherosclerosis 94 (1992) 213-221
19. Engbersen A.M., Franken D.G., Boers G.H., Stevens E.M., Trijbels F.J., and Blom H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 56 (1995) 142-150
20. Kang S.S., Wong P.W., Zhou J.M., Sora J., Lessick M., Ruggie N., et al. Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease. Metabolism 37 (1988) 611-613
21. Kang S.S., Zhou J., Wong P.W., Kowalisyn J., and Strokosch G. Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 43 (1998) 414-421
22. Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10 (1995) 111-113
23. Frantzen F., Faaren A.L., Alfheim I., and Nordhei A.K. An enzyme conversion immunoassay for determining total homocysteine in plasma or serum. Clin Chem 44 (1998) 311-316
24. Weisberg I., Tran P., Christensen B., Sibani S., and Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64 (1998) 169-172
25. Chen J., Stampfer M.J., Ma J., Selhub J., Malinow M.R., Hennekens C.H., et al. Influence of a methionine synthase (D919G) polymorphism on plasma homocysteine and folate levels and relation to risk of myocardial infarction. Atherosclerosis 154 (2001) 667-672
26. Jacques P.F., Bostom A.G., Selhub J., Rich S., Ellison R.C., Eckfeldt J.H., et al. National Heart, Lung and Blood Institute, National Institutes of Health. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI family heart study. Atherosclerosis 166 (2003) 49-55
27. Geisel J., Zimbelmann I., Schorr H., Knapp J.P., Bodis M., Hübner U., et al. Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med 39 (2001) 698-704
28. Brouwer D.A., Welten H.T., Reijngoud D.J., van Doormaal J.J., and Muskiet F.A. Plasma folic acid cutoff value, derived from its relationship with homocyst(e)ine. Clin Chem 44 (1998) 1545-1550
29. Carvo M.L., and Camilo M.E. Hyperhomocysteinemia is chronic alcohoism: relations to folic acid and vitamins B(6) and B(12) status. Nutrition 16 (2000) 296-302
30. Tsai M.Y., Welge B.G., Hanson N.Q., Bignell M.K., Vessey J., Schwichtenberg K., et al. Genetic causes of mild hyperhomocysteinemia in patients with premature occlusive coronary artery disease. Atherosclerosis 143 (1999) 163-170
31. Edrisinghe S.P. Homocysteine-indiced thrombosis. Br J Biomed Sci (2004) 40-70
32. Haynes W.G. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 16 (2002) 391-399
33. Nygard O., Vollset S.E., Refsum H., et al. Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc 274 (1995) 1526-1533
34. O'Callaghan P., Meleady R., Fitzgerald T., Graham I., and and the European COMAC group. Smoking and plasma homocysteine. Eur Heart J 23 (2002) 1580-1586
35. Bartecci, CE, Mackenzie, TD, Schrier, RW. The human costs of tobacco use. N Engl J Med 1994; 330: (pt1) 907-12, (pt2) 975-80.
36. Bellamy M.F., McDowell I.F., Ramsey M.W., Brownlee M., Bones C., Newcombe R.G., et al. Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in adults. Circulation 98 (1998) 1848-1852
37. Nappo F., De Rossa N., and Marfella R. Impairement of endothelial function by acute hyper-homocysteinemia and reversal by antioxidant vitamins. JAMA 281 (1996) 2113-2118
38. Tsai J.C., Perrella M.A., and Yoshizumi. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 91 (1994) 6369-6373
39. Freyer R.H., Wilson B.D., Gubler D.B., Fitzgerald L.A., and Rodgers G.M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 13 (1993) 1327-1333
40. Palareti G., Salardi S., and Piazzi S. Blood coagulation changes in homocystinuria: effects of pyridoxine and other specific therapy. J Pediatr 109 (1986) 1001-1006
41. van der Put N.M., Gabreels F., Stevens E.M.B., Smeitink J.A., Trijbels F.J., Eskes T.K., et al. A second common mutation in the methylene-tetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet 62 (1998) 1044-1051
42. Rothenbacher D., Fischer H.G., Hoffmeister A., Hoffmann M.M., März W., Bode G., et al. Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic and lipid parameters. Atherosclerosis 162 (2002) 193-200
43. Song C., Xing D., Tan W., Wei Q., and Lin D. Methylenetetrahydrofolate reductase polymorphisms increases risk of esophageal squamous cell carcinoma in a Chinese population. Cancer Res 61 (2001) 3272-3275
44. Castro R., Rivera I., Ravasco P., Jakobs C., Blom H.J., Camilo M.E., et al. 5,10-methylenetetrahydrofolate reductase 677C→T and 1298A→C mutations are genetic determinants of elevated homocysteine. Q J Med 96 (2003) 297-303
45. Franco R.F., Morelli V., Lourenco D., Maffei F.H., Tavella M.H., Piccinato C.E., et al. A second mutation in the methylenetetrahydrofolate reductase gene and the risk of venous thrombotic disease. Br J Haematol 105 (1999) 556-559
46. Friedman G., Goldschmidt N., Friedlander Y., Ben-Yehuda A., Selhub J., Babaey S., et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. J Nutr 129 (1999) 1656-1661
47. Zetterberg H., Coppala A., D'Angelo A., Palmér M., Rymo L., and Blennow. No association between the MTHFR A1298C and transcobalamin C776G genetic polymorphisms and hyper-homocysteinemia in thrombotic disease. Thromb Res 108 (2003) 127-131
48. Friso S., Girelli D., Trabetti E., Stranieri C., Olivieri O., Tinazzi E., et al. A1298C methyleneteetrahydrofolate reductase mutation and coronary artery disease: relationships with C677T polymorphism and homocysteine/folate metabolism. Clin Exp Med 2 (2002) 7-12
49. Zetterberg H., Rymo L., Coppola A., D'Angelo A., Spandidos D.A., and Blennow K. MTHFR C677T and A1298C polymorphisms and mutated sequences occurring in cis. Eur J Hum Genet 10 (2002) 579-582
50. Szczeklik A., Sanak M., Jankowski M., Dropinski J., Czachor R., Musial J., et al. Mutation A1298C methylenetetrahydrofolate reductase: risk for early coronary disease not associated with hyperhomocysteinemia. Am J Med Genet 101 (2001) 36-39
51. Morita H., Taguchi J., Kurihara H., Kitaoka M., Kaneda H., Kurihara Y., et al. Genetic polymorphism of 5,10 methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 95 (1997) 2032-2036
52. Kluijtmans L.A., Young I.S., Boreham C.A., Murray L., McMaster D., McNulty H., et al. Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 101 (2003) 2483-2488
53. Payne D.A., Chamoun A.J., Seifert S.I., and Stouffer G.A. MTHFR 677C→T mutation: a predictor of early-onset coronary artery disease. Thromb Res 103 (2001) 275-279
54. Schwahn B., and Rozen R. polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics 1 (2001) 189-201
55. van der Put N.M., van der Molen E.F., Kluijtmans L.A., Heil S.G., Trijbels J.M., Eskes T.K., et al. Sequence analysis of the coding region of human methionine synthase: relevance to hyperhomocysteinemia in neural-tube defects and vascular disease. Q J Med 90 (1997) 511-517
56. Wang X.L., Duarte N., Cai H., Adachi T., Sim A.S., and Cranney G. Relationship between total plasma homocysteine, polymorphisms of homocysteine metabolism related enzymes, risk factors and coronary artery disease in the Australian hospital-based population. Atherosclerosis 146 (1999) 133-140
57. Klerk M., Lievers K.J., Kluijtmans L.A., Blom H.J., de Heijer M., Schouten E.G., et al. The 2756A→G variant in the gene encoding methionine synthase: its relation with plasma homocysteine levels and risk of coronary heart disease in a Dutch case-control study. Thromb Res 110 (2003) 87-91
58. Hyndman M.E., Bridge P.J., Warnica J.W., Fick G., and Parsons H.G. Effect of heterozygosity for the methionine synthase 2756A→G mutation on the risk for recurrent cardiovascular events. Am J Cardiol 86 (2000) 1144-1146
59. Wang X.L., Cai H., Cranney G., and Wilcken D.E. The frequency of a common mutation of the methionine synthase gene in the Australian population and its relation to smoking and coronary artery disease. J Cardiovasc Risk 5 (1998) 289-295
60. Harmon D.L., Shields D.C., Woodside J.V., McMaster D., Yarnell J.W., Young I.S., et al. Methionine synthase D919G polymorphism is a significant but modest determinant of circulating homocysteine concentrations. Genet Epidemiol 17 (1999) 298-309
61. D'Angelo A., Coppola A., Madonna P., Fermo I., Pagano A., Mazzola G., et al. The role of vitamin B12 in fasting hyper-homocysteinemia and its interaction with the homozygous C677T mutation of the MTHFR gene. A case-control study of patients with early-onset thrombotic events. Thromb Haemost 83 (2000) 563-570
62. Morita H., Kurihara H., Sugiyama T., Sugiyama T., Hamada C., Sakai E., et al. Polymorphism of the methionine synthase gene: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population. Arterioscler Thromb Vasc Biol 19 (1999) 298-302
63. Wilson A., Platt R., Wu Q., Leclerc D., Christensen B., Yang H., et al. A common variant in methionine synthase reductase combined with low cobalamin increases risk for spina bifida. Mol Genet Metab 67 (1999) 317-323
64. Leclerc D., Wilson A., Dumas R., Gafuik C., Song D., Watkins D., et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci U S A 95 (1998) 3059-3064
65. Zavadakova P., Sokolova J., and Kozich V. Identification of novel polymorphisms and analysis of haplotypes in the methionine synthase reductase gene [abstract]. J Inherit Metab Dis 26 (2003) 36
66. Feix A., Winkelmayer W.C., Eberle C., Sunder-Plassmann G., and Födinger M. Methionine synthase reductase MTRR 66A→G has no effect on total homocysteine, folate, and vitamin B12 concentrations in renal transplant patients. Atherosclerosis 174 (2004) 43-48
67. Geisel J., Zimbelmann I., Schorr H., Knapp J.P., Bodis M., Hübner U., et al. Genetic defects as important factors for moderate hyperhomocysteinemia. Clin Chem Lab Med 39 (2001) 698-704
68. Brown C.A., McKinney K.Q., Kaufman J.S., Gravel R.A., and Rozen R. A common polymorphism in methionine synthase reductase increases risk of premature coronary artery disease. J Cardiovasc Risk 7 (2000) 197-200
69. Ray J.G., Langman L.J., Vermeulen M.J., Evrovski J., Yeo E.L., and Cole D.E.C. Genetics University of Toronto Thrombophilia Study in Women (GUTTSI): genetic and other risk factors for venous thromboembolism in women. Curr Control Trials Cardiovasc Med 2 (2001) 141-149
70. Jacques P.F., Rosenberg I.H., Rogers G., Selhub J., Bowman B.A., Gunter E.W., et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 69 (1999) 482-489
71. Hobbs C.A., Sherman S.L., Yi P., Hopkins S.E., Torfs C.P., Hine R.J., et al. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. Am J Hum Genet 67 (2000) 623